Frank D. Lee, Ph.D., Chief Executive Officer
Dr. Lee is founder of Dragonfly Sciences, and brings thirty years of experience in the life sciences spanning basic research to leadership in the biotechnology industry. Dr. Lee was founder, chairman and CEO of Adnexus Therapeutics of Waltham, MA which develops next generation biotherapeutics. Adnexus was acquired by Bristol Myers Squibb. Prior to Adnexus, he was Chief Technology Officer at Millennium Pharmaceuticals, now part of Takeda Pharmaceuticals, and helped Millennium become a leader in genomics based drug discovery, and was director of molecular biology research at DNAX/Schering-Plough, leading its programs in cytokine and growth factor research. Dr. Lee also co-founded Epitome Biosystems, a proteomics company acquired by Millipore Corporation. Dr. Lee was educated at the University of California, Berkeley, Stanford University and carried out post-doctoral research at MIT and Stanford University.
John S. Abrams, Ph.D., Vice President, Research and Development
Dr. Abrams brings to Dragonfly 30 years of experience in biopharmaceutical research and development with a focus on antibody technologies and therapeutic antibodies. He was formerly Director of Antibody Technologies at DNAX/Schering-Plough and Senior Director of Antibody Research and Development at Xenerex Biosciences, a division of Avanir Pharmaceuticals. He has directed the development of more than 70 monoclonal antibody panels to novel targets on the cutting edge of immunology and human clinical research and attained international recognition for developing antibodies against targets in inflammation, asthma, and allergy. Dr. Abrams received his education at the University of California, Berkeley and McGill University.
Jie Zhang, Ph.D., General Manager, Dragonfly Sciences, Shanghai
Dr. Zhang is a biotechnology research and business manager with over 20 years experience in biomedical related research and development in the US and China. As Associate Director of Drug discovery at Anesiva he managed multiple cross-functional projects and participated in market development for biomedical products. His scientific experience includes research in genetic variation, gene expression, systems biology and bioinformatics, and he has worked in cancer, inflammation, and cardiovascular disease. He has managed and teamed with project managers and scientists to meet regulatory deadlines. Dr. Zhang was educated at Nanjing University and the University of Utah and carried out post-doctoral work at Stanford University.
Lisa Alberta, Director of Finance and Administration
Ms. Alberta brings over 13 years of administrative experience in the biotechnology industry in the areas of sales, marketing, legal and finance. She has been with Dragonfly since its inception in 2005 and is responsible for business operations and finance. Prior to joining Dragonfly, she held positions at Adnexus Therapeutics and Applied Biosystems. Ms. Alberta has a degree from Wentworth Institute of Technology and studied accounting at Northeastern University.
Michael J. Gramer, Ph.D., Head of Process Development and Manufacturing
Dr. Gramer brings over 15 years of experience in diverse aspects of bioscience research, development, and manufacturing. He has extensive knowledge in the application of engineering principles to the biological sciences including CMC development, process optimization, scale up, and technology transfer; GMP manufacturing; intellectual property analysis; technology analysis and applied research. He held senior positions in process development at Genmab and PDL BioPharma. Dr. Gramer received his education at the University of Minnesota and Stanford University.
Cornelius S. Sobel, Ph.D., Head of European Development and Regulatory Affairs
Dr. Sobel has over 20 years of experience in the pharmaceutical industry with extensive experience in the areas of production, regulatory and intellectual property. He brings over ten years of working experience in the emerging field of biosimilars, and was a founder and Chief Scientific Officer of Biopartners AG. He led and managed the submission of two biosimilar applications to the EMEA, one of which was the first ever filed biosimilar, and the second resulted in successful marketing authorization for a biosimilar human growth hormone product. Prior to Biopartners, he was Head of Production, Clinical Development and Regulatory Affairs for biosimilars at Merck KGaA Biopharmaceuticals. Dr. Sobel was educated at the Institute for Molecular Biochemistry at the Johannes-Gutenberg University, Mainz, Germany.
Patricia Walicke, M.D., Ph.D, Head of Clinical Development
Dr. Walicke brings to Dragonfly over 15 years of experience in biopharmaceutical research and product development. She was formerly the Chief Medical Officer and Vice President of Clinical Affairs at OXiGENE Inc., Vice President of Clinical and Regulatory Affairs at Avidia, Inc. and Vice President of Clinical Development at Rinat Neurosciences, Inc. She has completed six INDs, designed and directed multiple Phase 1-3 clinical trials, completed one successful NDA, filed three patents, and has founded and built two productive clinical development groups in start-up biotechnology companies. In addition to her industrial experience, Dr. Walicke practiced neurology, and was on the faculty at UCSD. She has held adjunct appointments at UCSF, Emory University and Mercer University, School of Pharmacy. Dr. Walicke received her education at the Massachusetts Institute of Technology, Harvard Medical School, and Harvard University.
Elizabeth D. Moyer, Ph.D., Head of Nonclinical Development
Dr. Moyer has extensive experience directing all phases of pharmaceutical product development, including preclinical and clinical development, parenteral and ophthalmic drug formulation, CMC and regulatory affairs. She has worked in a wide variety of therapeutic areas and classes of drugs and biologics, including therapeutic monoclonal antibodies. She was formerly Senior Vice President of Product Development and Operations at Kinetek Pharmaceuticals Inc. and Director of Preclinical Development at Athena Neurosciences/ Elan Pharmaceuticals. Dr. Moyer obtained a Ph.D. in Biochemistry from SUNY Buffalo and conducted postdoctoral studies at SUNY Buffalo and Johns Hopkins University School of Medicine.